Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation

Aminah Jatoi, Jun ichi Yamashita, Jeff A Sloan, Paul J. Novotny, Harold E. Windschitl, Charles Lawrence Loprinzi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Megestrol acetate improves appetite and abrogates weight loss in some patients with advanced cancer. Moreover, preliminary studies suggest that progestational agents down-regulate interleukin-6 (IL-6), an inflammatory cytokine widely implicated in cancer-associated anorexia and weight loss. The present investigation examined the effects of megestrol acetate on IL-6 in an attempt to confirm these earlier, preliminary studies. The translational component of a large multi-institutional trial, this investigation examined 85 patients with advanced cancer and weight loss. Patients had been randomly assigned to receive megestrol acetate liquid suspension 800 mg/day + placebo tablets, or oral dronabinol tablets 2.5 mg b.i.d. + liquid placebo, or both agents. Other testing included serial physician-reported weight and patient-reported appetite and global quality of life. We found no significant differences in 1-month changes in serum IL-6 according to whether patients had been treated with megestrol acetate, dronabinol, or the combination: the mean differences ± standard deviation were -1.52±4.7 pg/ml, -0.62±3.5 pg/ml, and -0.2±3.1 pg/ml, respectively (P=0.40, by one-way ANOVA). Among the patients who noted alterations in their appetite over 1 month, we observed no significant changes in IL-6. Finally, changes in serum IL-6 were not associated with shifts in weight or global quality of life. Our investigation provides no evidence that megestrol acetate down-regulates IL-6 in patients with cancer-associated anorexia and weight loss.

Original languageEnglish (US)
Pages (from-to)71-75
Number of pages5
JournalSupportive Care in Cancer
Volume10
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Megestrol Acetate
Anorexia
Weight Loss
Interleukin-6
Down-Regulation
Appetite
Neoplasms
Dronabinol
Therapeutics
Tablets
Placebos
Quality of Life
Weights and Measures
Progestins
Serum
Suspensions
Analysis of Variance
Cytokines
Physicians

Keywords

  • Advanced cancer
  • Anorexia
  • Megestrol acetate
  • Weight loss

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

@article{0f6befeb7f164ba2b05311f250912e66,
title = "Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation",
abstract = "Megestrol acetate improves appetite and abrogates weight loss in some patients with advanced cancer. Moreover, preliminary studies suggest that progestational agents down-regulate interleukin-6 (IL-6), an inflammatory cytokine widely implicated in cancer-associated anorexia and weight loss. The present investigation examined the effects of megestrol acetate on IL-6 in an attempt to confirm these earlier, preliminary studies. The translational component of a large multi-institutional trial, this investigation examined 85 patients with advanced cancer and weight loss. Patients had been randomly assigned to receive megestrol acetate liquid suspension 800 mg/day + placebo tablets, or oral dronabinol tablets 2.5 mg b.i.d. + liquid placebo, or both agents. Other testing included serial physician-reported weight and patient-reported appetite and global quality of life. We found no significant differences in 1-month changes in serum IL-6 according to whether patients had been treated with megestrol acetate, dronabinol, or the combination: the mean differences ± standard deviation were -1.52±4.7 pg/ml, -0.62±3.5 pg/ml, and -0.2±3.1 pg/ml, respectively (P=0.40, by one-way ANOVA). Among the patients who noted alterations in their appetite over 1 month, we observed no significant changes in IL-6. Finally, changes in serum IL-6 were not associated with shifts in weight or global quality of life. Our investigation provides no evidence that megestrol acetate down-regulates IL-6 in patients with cancer-associated anorexia and weight loss.",
keywords = "Advanced cancer, Anorexia, Megestrol acetate, Weight loss",
author = "Aminah Jatoi and Yamashita, {Jun ichi} and Sloan, {Jeff A} and Novotny, {Paul J.} and Windschitl, {Harold E.} and Loprinzi, {Charles Lawrence}",
year = "2002",
doi = "10.1007/s00520-001-0310-7",
language = "English (US)",
volume = "10",
pages = "71--75",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation

AU - Jatoi, Aminah

AU - Yamashita, Jun ichi

AU - Sloan, Jeff A

AU - Novotny, Paul J.

AU - Windschitl, Harold E.

AU - Loprinzi, Charles Lawrence

PY - 2002

Y1 - 2002

N2 - Megestrol acetate improves appetite and abrogates weight loss in some patients with advanced cancer. Moreover, preliminary studies suggest that progestational agents down-regulate interleukin-6 (IL-6), an inflammatory cytokine widely implicated in cancer-associated anorexia and weight loss. The present investigation examined the effects of megestrol acetate on IL-6 in an attempt to confirm these earlier, preliminary studies. The translational component of a large multi-institutional trial, this investigation examined 85 patients with advanced cancer and weight loss. Patients had been randomly assigned to receive megestrol acetate liquid suspension 800 mg/day + placebo tablets, or oral dronabinol tablets 2.5 mg b.i.d. + liquid placebo, or both agents. Other testing included serial physician-reported weight and patient-reported appetite and global quality of life. We found no significant differences in 1-month changes in serum IL-6 according to whether patients had been treated with megestrol acetate, dronabinol, or the combination: the mean differences ± standard deviation were -1.52±4.7 pg/ml, -0.62±3.5 pg/ml, and -0.2±3.1 pg/ml, respectively (P=0.40, by one-way ANOVA). Among the patients who noted alterations in their appetite over 1 month, we observed no significant changes in IL-6. Finally, changes in serum IL-6 were not associated with shifts in weight or global quality of life. Our investigation provides no evidence that megestrol acetate down-regulates IL-6 in patients with cancer-associated anorexia and weight loss.

AB - Megestrol acetate improves appetite and abrogates weight loss in some patients with advanced cancer. Moreover, preliminary studies suggest that progestational agents down-regulate interleukin-6 (IL-6), an inflammatory cytokine widely implicated in cancer-associated anorexia and weight loss. The present investigation examined the effects of megestrol acetate on IL-6 in an attempt to confirm these earlier, preliminary studies. The translational component of a large multi-institutional trial, this investigation examined 85 patients with advanced cancer and weight loss. Patients had been randomly assigned to receive megestrol acetate liquid suspension 800 mg/day + placebo tablets, or oral dronabinol tablets 2.5 mg b.i.d. + liquid placebo, or both agents. Other testing included serial physician-reported weight and patient-reported appetite and global quality of life. We found no significant differences in 1-month changes in serum IL-6 according to whether patients had been treated with megestrol acetate, dronabinol, or the combination: the mean differences ± standard deviation were -1.52±4.7 pg/ml, -0.62±3.5 pg/ml, and -0.2±3.1 pg/ml, respectively (P=0.40, by one-way ANOVA). Among the patients who noted alterations in their appetite over 1 month, we observed no significant changes in IL-6. Finally, changes in serum IL-6 were not associated with shifts in weight or global quality of life. Our investigation provides no evidence that megestrol acetate down-regulates IL-6 in patients with cancer-associated anorexia and weight loss.

KW - Advanced cancer

KW - Anorexia

KW - Megestrol acetate

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=0036941020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036941020&partnerID=8YFLogxK

U2 - 10.1007/s00520-001-0310-7

DO - 10.1007/s00520-001-0310-7

M3 - Article

VL - 10

SP - 71

EP - 75

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 1

ER -